GenSight Biologics Announces the Closing of Approximately €500,000 of Additional Financing

GenSight Biologics Announces Publication on Predictors of Final Visual Outcome in Patients Treated with LUMEVOQ® Gene Therapy

GenSight Biologics Announces an Additional Financing Amounting to Approximately EUR 500,000 from Existing Shareholder

GenSight Biologics Reports Cash Position as of June 30, 2025

GenSight Biologics Announces the Closing of the Company’s c. €4 Million Private Placement

GenSight Biologics Announces Successful Completion of a Private Placement of Close to EUR 4 Million

GenSight Biologics Announces Significant Milestone in New Manufacturing Partnership with Catalent

GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ® Named Early Access Program (AAC) in France

GenSight Biologics Announces Approval of All Resolutions Supported by the Board of Directors at the Combined General Meeting of May 13, 2025

GenSight Biologics Annual General Meeting on May 13, 2025